Encision Inc (ECIA) — SEC Filings
Encision Inc (ECIA) — 17 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 6 8-K, 6 10-Q, 2 DEF 14A.
View Encision Inc on SEC EDGAR
Overview
Encision Inc (ECIA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: ENCISION INC. (ECIA) reported a significant increase in net loss for the three and six months ended September 30, 2025, alongside a decrease in total revenue. For the three months, net loss widened to $267,833 from $170,262 in the prior year, while total revenue declined by 13% to $1,528,050 from $1
Sentiment Summary
Across 17 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 1 mixed. The dominant filing sentiment for Encision Inc is neutral.
Filing Type Overview
Encision Inc (ECIA) has filed 6 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (17)
Risk Profile
Risk Assessment: Of ECIA's 14 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,528,050 |
| Net Income | -$267,833 |
| EPS | N/A |
| Debt-to-Equity | 1.17 |
| Cash Position | $71,731 |
| Operating Margin | -16.9% |
| Total Assets | $4,056,759 |
| Total Debt | $2,191,972 |
Key Executives
- Persons Employed by the Organization
- Non-PEO Named Executive Officers
- Dr. Michael J. Ennen
Industry Context
Encision Inc. operates in a competitive medical device market, likely focusing on energy-based surgical devices. The industry is characterized by rapid technological advancements, stringent regulatory approvals (FDA), and significant R&D investment. Companies often face pressure to demonstrate clinical efficacy and cost-effectiveness to gain market adoption and reimbursement.
Top Tags
10-Q (5) · financials (4) · medical-devices (4) · Medical Devices (3) · Going Concern (1) · Net Loss (1) · Revenue Decline (1) · Liquidity Risk (1) · Share Dilution (1) · OTC Bulletin Board (1)
Executive Compensation
From the most recent DEF 14A filing (Jul 14, 2025):
- Not Disclosed — PEO Member: Not Disclosed
- Not Disclosed — Non-PEO NEO Member: Not Disclosed
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (3 months) | $267,833 | Increased from $170,262 in prior year, indicating worsening profitability. |
| Net Loss (6 months) | $308,966 | Increased from $148,222 in prior year, highlighting a significant decline in financial performance. |
| Total Revenue (3 months) | $1,528,050 | Decreased by 13% from $1,755,388 in prior year, showing reduced sales. |
| Total Revenue (6 months) | $3,130,778 | Decreased by 7.5% from $3,386,318 in prior year, reflecting a sustained revenue downturn. |
| Cash Balance | $71,731 | Significant decrease from $257,433 at March 31, 2025, raising liquidity concerns. |
| Working Capital | $1,375,301 | Increased by $338,451 from March 31, 2025, primarily due to common stock issuance. |
| Proceeds from Common Stock Issuance | $500,000 | Helped increase shareholders' equity despite net loss, but not enough to offset cash burn. |
| Common Stock Shares Outstanding | 16,879,645 | Increased from 11,879,645 at March 31, 2025, indicating dilution. |
| Accumulated Deficit | $23,074,211 | Increased from $22,765,245 at March 31, 2025, reflecting ongoing losses. |
| Cash Funding Horizon | 2027 Q1 | Management estimates cash resources will only last until the first fiscal quarter of 2027. |
| Reporting Period End Date | 20250630 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Filing Date | 20250815 | The date the 10-Q report was officially submitted to the SEC. |
| Current Quarter | 2025-04-01 to 2025-06-30 | The specific period covered by the financial statements in this filing. |
| Prior Year Quarter | 2024-04-01 to 2024-06-30 | Provides a comparative period for financial analysis. |
| Conformed Period of Report | 2025-08-21 | The period to which the proxy statement relates |
Frequently Asked Questions
What are the latest SEC filings for Encision Inc (ECIA)?
Encision Inc has 17 recent SEC filings from Feb 2024 to Dec 2025, including 6 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ECIA filings?
Across 17 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Encision Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Encision Inc (ECIA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Encision Inc?
Key financial highlights from Encision Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ECIA?
The investment thesis for ECIA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Encision Inc?
Key executives identified across Encision Inc's filings include Persons Employed by the Organization, Non-PEO Named Executive Officers, Dr. Michael J. Ennen.
What are the main risk factors for Encision Inc stock?
Of ECIA's 14 assessed filings, 1 were flagged high-risk, 8 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Encision Inc?
Forward guidance and predictions for Encision Inc are extracted from SEC filings as they are enriched.